CDK4 and nonpapillary renal cell carcinoma: To explore the underlying mechanism by which CDK4/6 inhibitors modulate the stability of TSC1 in ccRCC, 786-O cells treated with or without palbociclib were subjected to mass spectrometry with IgG or TSC1 antibodies (Fig. 2a).